Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.048 USD | +2.76% | -2.94% | +90.58% |
May. 14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.58% | 37.65M | |
+51.50% | 59.28B | |
+41.93% | 40.94B | |
-5.80% | 40.17B | |
-5.56% | 28.69B | |
+11.02% | 26.63B | |
-22.11% | 18.89B | |
+29.69% | 12.46B | |
+1.30% | 12.42B | |
+26.71% | 12.26B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Transcript : Xilio Therapeutics, Inc. Presents at Citi's 2023 Virtual Oncology Leadership Summit, Feb-23-2023 09